JP2020506189A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506189A5
JP2020506189A5 JP2019541415A JP2019541415A JP2020506189A5 JP 2020506189 A5 JP2020506189 A5 JP 2020506189A5 JP 2019541415 A JP2019541415 A JP 2019541415A JP 2019541415 A JP2019541415 A JP 2019541415A JP 2020506189 A5 JP2020506189 A5 JP 2020506189A5
Authority
JP
Japan
Prior art keywords
mrna
cancer
optionally
encoding
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019541415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506189A (ja
JP7731656B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/058595 external-priority patent/WO2018144082A1/en
Publication of JP2020506189A publication Critical patent/JP2020506189A/ja
Publication of JP2020506189A5 publication Critical patent/JP2020506189A5/ja
Priority to JP2023146197A priority Critical patent/JP2023164537A/ja
Application granted granted Critical
Publication of JP7731656B2 publication Critical patent/JP7731656B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019541415A 2017-02-01 2017-10-26 Rna癌ワクチン Active JP7731656B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023146197A JP2023164537A (ja) 2017-02-01 2023-09-08 Rna癌ワクチン

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762453465P 2017-02-01 2017-02-01
US201762453444P 2017-02-01 2017-02-01
US62/453,465 2017-02-01
US62/453,444 2017-02-01
US201762558238P 2017-09-13 2017-09-13
US62/558,238 2017-09-13
PCT/US2017/058595 WO2018144082A1 (en) 2017-02-01 2017-10-26 Rna cancer vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023146197A Division JP2023164537A (ja) 2017-02-01 2023-09-08 Rna癌ワクチン

Publications (3)

Publication Number Publication Date
JP2020506189A JP2020506189A (ja) 2020-02-27
JP2020506189A5 true JP2020506189A5 (cg-RX-API-DMAC7.html) 2020-12-03
JP7731656B2 JP7731656B2 (ja) 2025-09-01

Family

ID=63040027

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019541415A Active JP7731656B2 (ja) 2017-02-01 2017-10-26 Rna癌ワクチン
JP2023146197A Pending JP2023164537A (ja) 2017-02-01 2023-09-08 Rna癌ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023146197A Pending JP2023164537A (ja) 2017-02-01 2023-09-08 Rna癌ワクチン

Country Status (11)

Country Link
US (2) US20190351040A1 (cg-RX-API-DMAC7.html)
EP (1) EP3576751A4 (cg-RX-API-DMAC7.html)
JP (2) JP7731656B2 (cg-RX-API-DMAC7.html)
KR (2) KR20190120233A (cg-RX-API-DMAC7.html)
CN (1) CN110505877A (cg-RX-API-DMAC7.html)
AU (1) AU2017397458B2 (cg-RX-API-DMAC7.html)
CA (1) CA3052255A1 (cg-RX-API-DMAC7.html)
MA (1) MA47401A (cg-RX-API-DMAC7.html)
RU (2) RU2022106357A (cg-RX-API-DMAC7.html)
SG (2) SG10202108307YA (cg-RX-API-DMAC7.html)
WO (1) WO2018144082A1 (cg-RX-API-DMAC7.html)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3009962T3 (en) 2014-04-23 2025-03-31 Modernatx Inc Nucleic acid vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
US20180289792A1 (en) 2015-10-22 2018-10-11 ModernaTX. Inc. Sexually transmitted disease vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
PE20181529A1 (es) 2015-10-22 2018-09-26 Modernatx Inc Vacunas de acido nucleico para el virus varicela-zoster (vzv)
AU2016366978B2 (en) 2015-12-10 2022-07-28 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
CN109475570B (zh) 2016-03-18 2022-04-01 免疫传感器公司 环二核苷酸化合物及使用方法
EP3445392A1 (en) * 2016-04-22 2019-02-27 CureVac AG Rna encoding a tumor antigen
KR102533456B1 (ko) 2016-05-18 2023-05-17 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
WO2018053209A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
CN110167587A (zh) 2016-11-11 2019-08-23 摩登纳特斯有限公司 流感疫苗
US11103578B2 (en) 2016-12-08 2021-08-31 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
EP3579885A4 (en) * 2017-02-07 2020-12-16 Nantcell, Inc. MAXIMIZING T CELL MEMORY, COMPOSITIONS AND RELATED METHODS
WO2018151816A1 (en) 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
EP3609534A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. WIDE SPECTRUM INFLUENZA VIRUS VACCINE
US11752206B2 (en) * 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
EP3668971B8 (en) 2017-08-18 2024-05-29 ModernaTX, Inc. Rna polymerase variants
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
KR20210038886A (ko) * 2018-06-27 2021-04-08 모더나티엑스, 인크. 개인화된 암 백신 에피토프 선택
WO2020022897A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020079448A1 (en) 2018-10-19 2020-04-23 The Francis Crick Institute Limited Novel cancer antigens and methods
CA3118947A1 (en) * 2018-11-07 2020-05-14 Modernatx, Inc. Rna cancer vaccines
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
AU2020208193A1 (en) * 2019-01-14 2021-07-29 BioNTech SE Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
CN113795579A (zh) 2019-02-20 2021-12-14 摩登纳特斯有限公司 用于共转录加帽的rna聚合酶变体
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
EP3937973A1 (en) * 2019-03-11 2022-01-19 Evaxion Biotech A/S Nucleic acid vaccination using neo-epitope encoding constructs
KR20210149727A (ko) 2019-03-11 2021-12-09 모더나티엑스, 인크. 유가식(fed-batch) 시험관내 전사 공정
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
CN114423449A (zh) * 2019-03-25 2022-04-29 俄亥俄州国家创新基金会 联合免疫调节及其用途
EP3962521A1 (en) * 2019-05-02 2022-03-09 University of Florida Research Foundation, Inc. Compositions for treatment of diffuse intrinsic pontine glioma
MA56060A (fr) * 2019-05-31 2022-04-06 Modernatx Inc Dosage de lymphocytes t ayant subi une expansion
AU2020289484A1 (en) * 2019-06-07 2021-12-23 Emory University KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN110172480B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 双抗原表位融合基因重组慢病毒载体、抗原提呈细胞和ctl细胞及其构建方法和应用
JP2022546417A (ja) * 2019-08-29 2022-11-04 チューリッヒ大学 最小mRNAおよびその使用
MX2022005980A (es) 2019-11-18 2022-09-07 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos.
WO2021119418A1 (en) * 2019-12-11 2021-06-17 Vanderbilt University Methods of synthesizing mrna and functional proteins from synthetic double stranded dna
US20230130155A1 (en) * 2020-01-30 2023-04-27 Modernatx, Inc. Mrnas encoding metabolic reprogramming polypeptides and uses thereof
CN115397459A (zh) * 2020-01-31 2022-11-25 基因泰克公司 用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
EP4099988A4 (en) * 2020-02-05 2024-03-13 University of Florida Research Foundation, Incorporated Rna-loaded nanoparticles and use thereof for the treatment of cancer
EP4118164A1 (en) 2020-03-11 2023-01-18 AdvanSix Resins & Chemicals LLC Surfactants for oil and gas production
EP4117624A1 (en) * 2020-03-11 2023-01-18 AdvanSix Resins & Chemicals LLC Surfactants for healthcare products
EP4136096A1 (en) * 2020-04-17 2023-02-22 The Francis Crick Institute Limited Antigen pool
WO2021213924A1 (en) 2020-04-22 2021-10-28 BioNTech SE Coronavirus vaccine
US11130787B2 (en) * 2020-06-11 2021-09-28 MBF Therapeutics, Inc. Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods
KR20230034333A (ko) 2020-07-02 2023-03-09 라이프 테크놀로지스 코포레이션 트리뉴클레오티드 캡 유사체, 제조 및 이의 용도
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
JP7690222B2 (ja) * 2020-08-04 2025-06-10 プロジェニア インコーポレイテッド 動力学的制御が可能なアジュバントを含むmRNAワクチン
MX2023001782A (es) 2020-08-12 2023-05-22 Actym Therapeutics Inc Vacunas, productos terapéuticos y plataformas de administración de arn a base de bacterias inmunoestimuladoras.
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
IL302215A (en) 2020-10-20 2023-06-01 St Pharm Co Ltd Oligonucleotide for 5'-capped rna synthesis
EP4232036A4 (en) * 2020-10-22 2024-10-30 The Regents of University of California MONOAMINE OXIDASE BLOCKADE THERAPY FOR CANCER TREATMENT BY REGULATION OF TUMOR-ASSOCIATED MACROPHAGES (TAMs)
WO2022120560A1 (zh) * 2020-12-08 2022-06-16 深圳市瑞吉生物科技有限公司 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用
WO2022140278A1 (en) * 2020-12-21 2022-06-30 University Of Florida Research Foundation, Inc. Multilamellar rna nanoparticle vaccine against cancer
CN114717229B (zh) * 2021-01-05 2024-09-10 麦塞拿治疗(香港)有限公司 治疗性mRNA的无细胞和无载体体外RNA转录方法和核酸分子
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
CN117677389A (zh) * 2021-03-26 2024-03-08 摩登纳特斯有限公司 百日咳疫苗
NL2028681B1 (en) * 2021-04-02 2022-10-17 Nutcracker Therapeutics Inc Materials and methods for generating antigen-specific t cells and treating diseases
CN113186285B (zh) * 2021-05-10 2022-05-24 深圳市展行生物有限公司 一种辅助诊断胃癌的方法及其使用的miRNA组合
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
CN113577258B (zh) * 2021-07-31 2024-04-16 山东兴瑞生物科技有限公司 一种双靶点mRNA疫苗及其制备方法
CN115703714B (zh) * 2021-08-13 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
WO2023030635A1 (en) * 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
EP4147713A1 (en) * 2021-09-13 2023-03-15 OncoDNA A rna vaccine comprising an rna pool generated from a double-stranded dna pool
EP4147712A1 (en) 2021-09-13 2023-03-15 OncoDNA Method to generate a double-stranded dna pool encoding neoantigens of a tumor of a patient
WO2023036997A1 (en) 2021-09-13 2023-03-16 Oncodna Method to generate personalized neoantigens of a tumor of a patient
JP2024542173A (ja) 2021-11-09 2024-11-13 アクティム・セラピューティクス・インコーポレイテッド マクロファージを処置に適している表現型に変換するための免疫刺激細菌および処置のための対象の同定のためのコンパニオン診断法
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
EP4458843A4 (en) * 2021-12-31 2025-07-09 Guangzhou Nat Laboratory MRNA VACCINE
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN119866224A (zh) * 2022-07-28 2025-04-22 加拿大干细胞技术公司 编码连接抗原的多核苷酸以及其用途
CN115992152A (zh) * 2022-09-22 2023-04-21 浙江大学医学院附属第一医院 一种用于乙型肝炎病毒治疗性mRNA疫苗及其制备方法与应用
CN120019151A (zh) * 2022-10-07 2025-05-16 国立大学法人筑波大学 核酸构建物及蛋白复合体的设计方法及制造方法
AU2023363971A1 (en) * 2022-10-19 2025-05-01 Kalivir Immunotherapeutics, Inc. Nucleic acids encoding soluble pd-1 and il-12 and uses thereof
CN120225259A (zh) * 2022-10-31 2025-06-27 磨石生物公司 组合组无细胞dna监测
EP4612301A1 (en) * 2022-11-03 2025-09-10 ModernaTX, Inc. Chemical stability of mrna
EP4364752A1 (en) 2022-11-07 2024-05-08 OncoDNA Improved vaccine
CN116970614A (zh) * 2022-12-29 2023-10-31 达冕疫苗(广州)有限公司 编码ny-eso-1的核糖核酸疫苗的组合物和方法
EP4651888A1 (en) * 2023-01-17 2025-11-26 The University Of Hong Kong Cancer immunotherapy by delivery of mrna
CN119055671A (zh) * 2023-05-23 2024-12-03 源生生物科技(青岛)有限责任公司 包含miRNA的活性成分及其应用
WO2025054383A1 (en) * 2023-09-06 2025-03-13 Modernatx, Inc. Chemical stability of mrna
WO2025080869A1 (en) * 2023-10-11 2025-04-17 The Regents Of The University Of California Pancreatic cancer immunotherapy using cationic lipid and polymer nanocarriers for co-delivery of kras neoantigens and sting and/or other immunomodulators to boost the cancer immunity cycle and treat liver metastasis
WO2025117816A1 (en) * 2023-12-01 2025-06-05 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
WO2025153053A1 (en) * 2024-01-17 2025-07-24 Abogen Biosciences (Shanghai) Co., Ltd. Composition and methods for inducing antigen specific immunity against kras mutant cells
WO2025158069A1 (en) * 2024-01-25 2025-07-31 Rheinische Friedrich-Wilhelms-Universität Bonn CONSTRUCT COMPRISING mRNA-STRAND AND RETINOIC ACID-INDUCIBLE GENE I (RIG-I)-LIGAND(S), PHARMACEUTICAL COMPOSITION AND KIT COMPRISING THE SAME
CN118389553A (zh) * 2024-03-01 2024-07-26 中国科学技术大学 免疫增效rna分子及其组合物、疫苗与试剂盒
CN117883558B (zh) * 2024-03-15 2024-06-14 山东兴瑞生物科技有限公司 靶向肝肿瘤个性化mRNA疫苗的制备方法
CN119874872B (zh) * 2025-01-17 2025-11-25 武汉大学 一种mita铰链区突变多肽及其在自身免疫性疾病中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
DK3023788T3 (da) * 2010-05-14 2020-04-27 Massachusetts Gen Hospital Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
LT3473267T (lt) 2011-05-24 2021-11-25 BioNTech SE Individualizuotos vakcinos nuo vėžio
RU2585528C2 (ru) * 2011-08-16 2016-05-27 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевый агент и способ предсказания терапевтического эффекта для пациентов с раком ободочной и прямой кишки с мутацией гена kras
HUE041800T2 (hu) * 2011-08-31 2019-05-28 Glaxosmithkline Biologicals Sa Pegilált liposzómák immunogént kódoló RNS bejuttatására
WO2013151663A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US10226528B2 (en) 2013-03-15 2019-03-12 The Trustees Of The University Of Pennsylvania Vaccines with biomolecular adjuvants
JP6558699B2 (ja) * 2013-10-01 2019-08-14 国立大学法人三重大学 抗原提示を促進するエピトープ間配列を含むt細胞誘導ワクチン
ES3009962T3 (en) 2014-04-23 2025-03-31 Modernatx Inc Nucleic acid vaccines
US20170204152A1 (en) * 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
SG10201907164SA (en) * 2015-04-22 2019-09-27 Curevac Ag Rna containing composition for treatment of tumor diseases
EP3307305A4 (en) * 2015-06-10 2019-05-22 Modernatx, Inc. TARGETED ADAPTIVE VACCINES
MA42543A (fr) * 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
JP2018532777A (ja) * 2015-10-22 2018-11-08 モデルナティーエックス, インコーポレイテッド 癌ワクチン
RU2765874C2 (ru) * 2016-10-26 2022-02-04 МОДЕРНАТиЭкс, ИНК. Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения

Similar Documents

Publication Publication Date Title
JP2020506189A5 (cg-RX-API-DMAC7.html)
RU2019127381A (ru) Противораковые рнк-вакцины
JP6959970B2 (ja) 抗ヒトパピローマウイルス16 e6 t細胞受容体
ES3033286T3 (en) Conjugated antibody or bispecific t-cell engager which selectively binds either tcr beta constant region 1 (trbc1) or trbc2
JP2020514321A5 (cg-RX-API-DMAC7.html)
ES2727154T3 (es) Combinación
ES2899779T3 (es) Receptores antigénicos quiméricos dirigidos a receptor acoplado a proteína G y usos de los mismos
JP2024105296A5 (cg-RX-API-DMAC7.html)
JP7612591B2 (ja) 抗clec2d抗体及びその使用方法
CN115947846A (zh) 一种抗pd-l1纳米抗体及其衍生物和用途
Damasio et al. The role of T-cells in head and neck squamous cell carcinoma: from immunity to immunotherapy
BR112021000399A2 (pt) Anticorpos antimesotelina
Thongchot et al. Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy
US20210015891A1 (en) Interleukin-18 mimics and methods of use
JP2022520285A (ja) 低酸素応答性キメラ抗原受容体
JP2022529059A (ja) バリアントicosリガンド(icosl)融合タンパク質の方法および使用
CA3211272A1 (en) Chimeric proteins in autoimmunity
Jacob et al. Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology
JP7541390B2 (ja) 免疫チェックポイント分子と結合可能な分子が融合したタンパク質およびその用途
TW201938160A (zh) 以ccr2拮抗劑治療實體腫瘤的方法
JP2005515159A (ja) 癌を治療するためのrankアンタゴニストの使用
CN114685675B (zh) 双特异性抗体及其在治疗癌症中的用途
CN118510794A (zh) 白细胞介素-12变体和使用方法
KR20110101134A (ko) 수지상 세포를 표적으로 하는 조성물
WO2021113648A1 (en) Affinity molecules that direct the metabolism and polarization of macrophages and synergize the immune checkpoint blockade therapy